Aziyo Investor Relations.

Aziyo is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. From our proprietary tissue processing platforms, we have developed a portfolio of advanced regenerative medical products that are designed to be very similar to natural biological material.

Aziyo Investor Relations.

Learn the Latest Aziyo Updates.

Aziyo Biologics Reports Record Full Year 2022 Revenues

Mar 22, 2023

SILVER SPRING, Md., March 22, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported...

Aziyo Biologics and Sientra Announce SimpliDerm® Partnership to Improve Women’s Access to Biologics for Soft Tissue Reconstruction

Mar 22, 2023

SILVER SPRING, Md. and IRVINE, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, and Sientra, Inc....

Aziyo Biologics Provides Update on FDA Submission for CanGaroo® RM Antibacterial Envelope

Mar 20, 2023

SILVER SPRING, Md., March 20, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, provides an update on its submission to the U.S....

Filing date	Form	Filing Group	View
Mar 23, 2023	10-K	Annual Filings	View HTML 0001558370-23-004475.pdf 0001558370-23-004475.rtf 0001558370-23-004475.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Mar 22, 2023	8-K	Current Reports	View HTML 0001104659-23-035590.pdf 0001104659-23-035590.rtf 0001104659-23-035590.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Mar 21, 2023	SC 13G/A	Other	View HTML 0001633055-23-000005.pdf 0001633055-23-000005.rtf 0001633055-23-000005.xls

Aziyo Investor Relations.

Aziyo Investor Relations.

Learn the Latest Aziyo Updates.

Aziyo Biologics Reports Record Full Year 2022 Revenues

Aziyo Biologics and Sientra Announce SimpliDerm® Partnership to Improve Women’s Access to Biologics for Soft Tissue Reconstruction

Aziyo Biologics Provides Update on FDA Submission for CanGaroo® RM Antibacterial Envelope

Latest SEC Filings.

Events & Presentations

4Q 2022 Financial Results Presentation

Aziyo Biologics Q4 2022 Financial Results Call

Mar 22, 2023 4:30 PM EDT

Aziyo Biologics at the Cowen 43rd Annual Health Care Conference

Mar 06, 2023 9:50 AM EST

Quarterly Reports

Interested in Email Alerts?

Corporate Headquarters